论文部分内容阅读
近年来,免疫治疗在血液系统肿瘤治疗中取得了长足进步,特别是嵌合抗原受体修饰的T细胞(chimeric antigen receptor modified T cells,CART cells)在B细胞系血液肿瘤治疗中的突破,为血液肿瘤的治疗提供了新的可选方案。其中以CD19为靶点的CART疗法由于效果显著、研究广泛,已成为多数临床研究机构开展基因修饰T细
In recent years, immunotherapy has made great progress in the treatment of hematological malignancies. In particular, the breakthrough of chimeric antigen receptor modified T cells (CART cells) in the treatment of hematological tumors of B cell line is The treatment of hematologic tumors offers a new alternative. Which CD19 as a target of CART therapy due to the significant effect of extensive research has become the majority of clinical research institutions to carry out gene modification T fine